#United States
#Newport Beach
#Hoag Family Cancer Institute
#Steven Grossman
#Executive Medical Director
Steven Grossman, M.D., Ph.D., Appointed to Lead Hoag Family Cancer Institute
On April 28, 2025, Hoag announced a significant milestone in its commitment to cancer research and treatment. The organization has successfully recruited Dr. Steven Grossman, a distinguished physician-scientist with extensive expertise in gastrointestinal cancers, as the new Executive Medical Director of the Hoag Family Cancer Institute.
Dr. Grossman comes to Hoag from the renowned USC Norris Comprehensive Cancer Center and Keck School of Medicine, where he held the position of Deputy Director for Cancer Services and Physician-in-Chief. His recruitment is seen as a pivotal move for Hoag, enhancing its efforts to advance cancer care and solidifying its growth trajectory in this critical domain.
Hoag’s President and CEO, Robert T. Braithwaite, expressed enthusiasm about Dr. Grossman’s appointment, stating that his leadership would bolster Hoag's innovative capabilities in translating research into effective patient care, not only in Orange County but on a global scale. "We are excited to welcome him to our esteemed team of physicians, scientists, and caregivers," Braithwaite remarked.
This transition occurs at a significant time as Hoag accelerates its initiatives in cancer research, treatment, and prevention. A $1 billion investment is underway to expand Hoag's Irvine campus, which will introduce the Cancer Digestive Hospital Pavilion. This new facility is emphasizing Hoag’s commitment to dedicated cancer care offerings that leverage state-of-the-art clinical trials designed to enhance patient outcomes significantly.
Dr. Grossman’s extensive background in clinical research, particularly in gastrointestinal malignancies, aligns with Hoag’s philosophy of employing a “privademic” model that harmonizes the advantages of both private practice and academic medicine. He noted his admiration for Hoag’s ability to provide cutting-edge therapies in personalized clinical settings. "Hoag's multidisciplinary approach rivals those of traditional academic institutions, ensuring comprehensive care that considers patients’ physical, mental, and emotional needs," Dr. Grossman stated.
Hoag leads in clinical trials, with offerings exceeding 100 unique studies focused on cancer. These groundbreaking initiatives, partly funded through philanthropic efforts, aim to explore and validate innovative strategies in drug therapies and surgical methods. Among Hoag's noteworthy projects is the Precision Medicine Program, which integrates advanced genomic technologies to deliver the latest treatment paradigms including personalized therapy.
The mission driving these efforts is to significantly impact cancer prevention, timely diagnosis, and effective treatment. For instance, Hoag’s Anita Erickson Pancreatic Cancer Early Detection Program stands out as one of the few early detection initiatives across the nation and the first in Southern California. It utilizes a team of specialists—including genetic counselors and surgeons—to educate patients on risk factors and facilitate early-stage cancer identification through a combination of labs and imaging technologies.
Philanthropic support is crucial for Hoag's ability to maintain such ambitious treatment, prevention, and research initiatives. The Circle 1000, a philanthropic group dedicated to the Hoag Family Cancer Institute, has raised substantial funds exceeding $25 million to enhance cancer care at the facility, playing a fundamental role in the recruitment of Dr. Grossman.
Academically, Dr. Grossman boasts an impressive qualification profile with an A.B. from Princeton University, an M.D., and a Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago. He completed his residency at Brigham and Women's Hospital, followed by a postdoctoral fellowship at Harvard Medical School, and is also fellowship-trained in Medical Oncology through the Dana-Farber Cancer Institute.
Dr. Grossman is excited to join Hoag's distinguished team, known for its innovation, collaboration, and compassion in patient care. He remarked, "Hoag's dedication to challenging the boundaries of patient care is well-established, and I am thrilled to join this dynamic team to further its mission to improve cancer outcomes."
About Hoag:
Hoag is a nonprofit health care delivery system located in Orange County, California, recognized for providing world-class, personalized medical care. The organization comprises 1,800 top-level physicians, operates 17 urgent care facilities, 11 health and wellness centers, and two award-winning hospitals. It specializes in various fields, including cancer treatment, digestive health, heart and vascular care, neurosciences, and orthopedics through the Hoag Orthopedic Institute. Hoag excels in delivering comprehensive care and has been deeply committed to community health and innovative medical solutions. It is also recognized as the highest-ranked hospital in Orange County by U.S. News & World Report and the only OC hospital listed among California's top ten hospitals.
Dr. Grossman comes to Hoag from the renowned USC Norris Comprehensive Cancer Center and Keck School of Medicine, where he held the position of Deputy Director for Cancer Services and Physician-in-Chief. His recruitment is seen as a pivotal move for Hoag, enhancing its efforts to advance cancer care and solidifying its growth trajectory in this critical domain.
Hoag’s President and CEO, Robert T. Braithwaite, expressed enthusiasm about Dr. Grossman’s appointment, stating that his leadership would bolster Hoag's innovative capabilities in translating research into effective patient care, not only in Orange County but on a global scale. "We are excited to welcome him to our esteemed team of physicians, scientists, and caregivers," Braithwaite remarked.
This transition occurs at a significant time as Hoag accelerates its initiatives in cancer research, treatment, and prevention. A $1 billion investment is underway to expand Hoag's Irvine campus, which will introduce the Cancer Digestive Hospital Pavilion. This new facility is emphasizing Hoag’s commitment to dedicated cancer care offerings that leverage state-of-the-art clinical trials designed to enhance patient outcomes significantly.
Dr. Grossman’s extensive background in clinical research, particularly in gastrointestinal malignancies, aligns with Hoag’s philosophy of employing a “privademic” model that harmonizes the advantages of both private practice and academic medicine. He noted his admiration for Hoag’s ability to provide cutting-edge therapies in personalized clinical settings. "Hoag's multidisciplinary approach rivals those of traditional academic institutions, ensuring comprehensive care that considers patients’ physical, mental, and emotional needs," Dr. Grossman stated.
Hoag leads in clinical trials, with offerings exceeding 100 unique studies focused on cancer. These groundbreaking initiatives, partly funded through philanthropic efforts, aim to explore and validate innovative strategies in drug therapies and surgical methods. Among Hoag's noteworthy projects is the Precision Medicine Program, which integrates advanced genomic technologies to deliver the latest treatment paradigms including personalized therapy.
The mission driving these efforts is to significantly impact cancer prevention, timely diagnosis, and effective treatment. For instance, Hoag’s Anita Erickson Pancreatic Cancer Early Detection Program stands out as one of the few early detection initiatives across the nation and the first in Southern California. It utilizes a team of specialists—including genetic counselors and surgeons—to educate patients on risk factors and facilitate early-stage cancer identification through a combination of labs and imaging technologies.
Philanthropic support is crucial for Hoag's ability to maintain such ambitious treatment, prevention, and research initiatives. The Circle 1000, a philanthropic group dedicated to the Hoag Family Cancer Institute, has raised substantial funds exceeding $25 million to enhance cancer care at the facility, playing a fundamental role in the recruitment of Dr. Grossman.
Academically, Dr. Grossman boasts an impressive qualification profile with an A.B. from Princeton University, an M.D., and a Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago. He completed his residency at Brigham and Women's Hospital, followed by a postdoctoral fellowship at Harvard Medical School, and is also fellowship-trained in Medical Oncology through the Dana-Farber Cancer Institute.
Dr. Grossman is excited to join Hoag's distinguished team, known for its innovation, collaboration, and compassion in patient care. He remarked, "Hoag's dedication to challenging the boundaries of patient care is well-established, and I am thrilled to join this dynamic team to further its mission to improve cancer outcomes."
About Hoag:
Hoag is a nonprofit health care delivery system located in Orange County, California, recognized for providing world-class, personalized medical care. The organization comprises 1,800 top-level physicians, operates 17 urgent care facilities, 11 health and wellness centers, and two award-winning hospitals. It specializes in various fields, including cancer treatment, digestive health, heart and vascular care, neurosciences, and orthopedics through the Hoag Orthopedic Institute. Hoag excels in delivering comprehensive care and has been deeply committed to community health and innovative medical solutions. It is also recognized as the highest-ranked hospital in Orange County by U.S. News & World Report and the only OC hospital listed among California's top ten hospitals.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.